No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of valsartan due to OAT inhibtion. Monitor for signs of toxicity (ie. SCr, K+). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - monitor INR more closely after initiation of darolutamide therapy or dose changes. Potential increased toxicity of warfarin (bleeding) due to enzyme inhibition. Titrate warfarin dose to target INR.
No clinically significant drug interactions identified.